ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
This year at OneMedForum San Francisco, OneMedPlace offered 17 workshop sessions on a variety of subjects helping investors grow their businesses.
Recent controversy surrounding FDA’s processes for premarket review of medical devices has ignited a discussion among researchers in hope of getting to the crux of the issue.
The cruciate ligaments of the knee are vital for a wide range of activities, from bending over to pick up something on the ground to running bases at a softball game.
Abraxas made the list of top 20 ambulatory EMR software vendors for single physician practices, as well as for practices with 2 to 5, 26 to 99, 100 to 249 and 250 or more physicians.
“The Provider as a System” will discuss how innovations in information management and technology coupled with changes in the business landscape are transforming the delivery of healthcare.
Their initial collaboration will target atopic dermatitis and related conditions.
MannKind is a biopharmaceutical company that actualizes therapeutics for the treatment of diabetes and cancer, and has also developed a novel inhalation-based drug delivery system that enables enhanced…
Infinity Pharmaceuticals is a biopharmaceutical company that has developed a targeted drug development platform to actualize small molecule inhibitors against specific bioactive proteins that play critical roles in biological…
According to the American Heart Association, approximately 325,000 people per year die of a heart attack before they can reach a hospital.
Copyright © 2024 | WordPress Theme by MH Themes